Yeah, I don't really think MRKR is in a position to have to call anyone, quite the opposite. TPIV 100/200 along with PolyStart appear to be gamechanging vaccine treatments, while MultiTAA is thus far proving in trials to be superior to current cancer treatments. If the trials continue to prove the science is credible, MRKR could quickly become the leader in the treatment of many forms of cancer.
There are eventually tens of billions of dollars at stake, both to MRKR and many big pharma companies that currently own expensive cancer drugs. How Peter addresses the buyout offers is certainly critical, but thankfully we've hired the expertise of Nadia and Steven since the pancreatic fiasco to avoid any such mistakes.
Share price may be low, with 4+m short shares still in play, but as the science continues to prove itself I'd think it's only a matter of time before that changes drastically. But we were screwed by them once under suspicious circumstances, so shorters influence going forward can't be ignored.
Bottom line, as both TPIV vaccines and MultiTAAs look to be golden, it's only a matter of TIME before MRKR accepts some form of buyout they simply can't refuse.
News 
Market Data 
Discover 
